Australia's biotech firm BCAL Diagnostics falls in market debut

BCAL Diagnostics

21/07/2021 04:58

** Shares of biotechnology company  BDX.AX  fall as much as
6% to A$0.235, below the listing price of A$0.25, in ASX debut
    ** BCAL raised A$10 mln ($7.31 mln) in its IPO at an issue
price of A$0.25 per share  urn:newsml:reuters.com:*:nASXbZzTWm
    ** Co is developing a non-invasive, low-cost, blood-based
diagnostic test to detect breast cancer
    ** Says it will use funds raised from the IPO to conduct
clinical studies and deliver documentation for regulatory
submissions in key jurisdictions
    
    



($1 = 1.3680 Australian dollars)

 (Reporting by Riya Sharma in Bengaluru)
 ((Riya.Sharma@thomsonreuters.com;))